Assistant Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Elahe A. Mostaghel, MD
|
|
Give Review
Dr. Elahe A. Mostaghel is an expert in the field of Oncology. He studied medicine at Duke University School of Medicine. Duke University School of Medicine is one of the top medical schools in the US. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. He over the years received 1 awards: "Regional Top Doctor". Elahe Mostaghel is a published doctor. He has 46 papers published. The most current publication "Coreceptor-independent T cell activation in mice expressing MHC class II molecules mutated in the CD4 binding domain." Elahe Mostaghel accepts all Medicare patients.
Publications
- In Reply to Bhattacharyya et al.
- External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens.
- The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate Cancer.
- The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis.
- Minireview: SLCO and ABC Transporters: A Role for Steroid Transport in Prostate Cancer Progression.
- Practical guide to the use of abiraterone in castration resistant prostate Cancer.
- Glucocorticoids and prostate Cancer treatment: friend or foe?
- Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer.
- Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study.
- Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-...
- Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and An...
- Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate Cancer.
- Impact of Male Hormonal Contraception on ProState Androgens and Androgen Action in Healthy Men: A Randomized, Controlled Trial.
- New hormonal therapies for castration-resistant prostate Cancer.
- Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate Cancer and is upregulated by treatment with CYP17A1 inhibitors.
- Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate Cancer: Induction of steroidogenesis and androgen receptor splice variants.
- Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.
- Expression of SLCO transport genes in castration-resistant prostate Cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate Cancer outcomes.
- Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter proState androgen action in healthy men: a randomized-controlled t...
- Castration resistance in human prostate Cancer is conferred by a frequently occurring androgen receptor splice variant.
- Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate Cancer chemoprevention.
- Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate Cancer progression.
- Castration-resistant prostate Cancer: targeting androgen metabolic pathways in recurrent disease.
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.
- ProState tissue androgens: history and current clinical relevance.
- Maintenance of intratumoral androgens in metastatic prostate Cancer: a mechanism for castration-resistant tumor growth.
- Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate Cancer.
- The basic biochemistry and molecular events of hormone therapy.
- Persistent intraprostatic androgen concentrations after medical castration in healthy men.
- Pulmonary surfactant proteins A and D directly suppress CD3+/CD4+ Cell function: evidence for two shared mechanisms.
- A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate Cancers than in primary prostate ...
- Abiraterone in the treatment of metastatic castration-resistant prostate Cancer.
- Prostate Cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
- Effect of testosterone replacement therapy on proState tissue in men with late-onset hypogonadism: a randomized controlled trial.
- Intraprostatic steroidogenic enzymes - letter.
- Genomic strategy for targeting therapy in castration-resistant prostate Cancer.
- Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry.
- Intracrine androgen metabolism in prostate Cancer progression: mechanisms of castration resistance and therapeutic implications.
- A molecular correlate to the Gleason grading System for prostate adenocarcinoma.
- Coreceptor-independent T Cell activation in mice expressing MHC class II molecules mutated in the CD4 binding domain.
- Surfactant protein D enhances bacterial antigen presentation by bone marrow-derived dendritic Cells.
- Disruption of the CD4-major histocompatibility complex class II interaction blocks the development of CD4(+) T Cells in vivo.
- Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation.
Schools
Duke University
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- First Choice Health
- Coop Core
- Medicare Advantage PFFS
- HealthSmart
- Medicaid
- Medicare MCR
- Molina
- Providence Health Plans
- Preferred Provider Network PPN
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
Education
-
University of Washington -
UCSF -
Duke University School of Medicine
Drug Facts
| NPI NUMBER | 1144267873 | |
| NPPES Provider LastName | MOSTAGHEL | |
| NPPES Provider FirstName | ELAHE | |
| NPPES Provider ZIPCode | 98109 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 55.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1144267873 |
| Last Name Of The Provider | MOSTAGHEL |
| First Name Of The Provider | ELAHE |
| View All |
Similar Doctors
|
|
Dr. Bart L. Scott, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David G. Maloney, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel B. Martin, MD |
|
|
Dr. Erin D. Ellis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Thompson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert B. Einstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heather H. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan D. Cassaday, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cassian K. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anne C. Silva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marco B. Mielcarek, MD
This Doctor is OpenDoctor Recommended.
|